- Home
- MOS vs RVMD Comparison
MOS vs RVMD Comparison
Compare MOS & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MOS | RVMD |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 7.5B |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MOS | RVMD |
|---|---|---|
| Price | $24.50 | $77.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 18 |
| Target Price | $34.93 | ★ $77.11 |
| AVG Volume (30 Days) | ★ 8.0M | 2.4M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | ★ 3.59% | N/A |
| EPS Growth | ★ 235.95 | N/A |
| EPS | ★ 3.87 | N/A |
| Revenue | ★ $11,894,600,000.00 | N/A |
| Revenue This Year | $16.57 | N/A |
| Revenue Next Year | $1.03 | $537.73 |
| P/E Ratio | $6.34 | ★ N/A |
| Revenue Growth | ★ 3.83 | N/A |
| 52 Week Low | $22.36 | $29.17 |
| 52 Week High | $38.23 | $78.17 |
Technical Indicators
Market Signals| Indicator | MOS | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 34.69 | 87.86 |
| Support Level | $23.35 | $69.50 |
| Resistance Level | $24.42 | $78.17 |
| Average True Range (ATR) | 0.70 | 2.57 |
| MACD | 0.14 | 0.70 |
| Stochastic Oscillator | 38.89 | 98.80 |
Price Performance
Historical ComparisonAbout MOS Mosaic Company (The)
Mosaic is one of the largest phosphate and potash producers in the world. The company's assets include phosphate rock mines in Florida and Peru and potash mines in Saskatchewan and New Mexico. Mosaic also runs a large fertilizer distribution operation in Brazil through its Mosaic Fertilizantes business.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.